|
| Holoprosencephaly-1 (2) | 21q22.3 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 0.717 |
| Tukel syndrome (2) | 21q22 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 0.717 |
| Dermatitis, atopic, 603165 (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| Eosinophilia, familial (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| Glaucoma 1, open angle, M (2) | 5q22.1-q32 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| Hemangioma, capillary infantile (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| Paget disease of bone, 602080 (2) | 5q31 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {?Allergy and asthma susceptibility} (2) | 5q31.1 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Autoimmune thyroid disease, susceptibility to, 2} (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Celiac disease, susceptibility to, 2} (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Diabetes mellitus, insulin-dependent, 18} (2) | 5q31.1-q33.1 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Inflammatory bowel disease-5}, 266600 (2) | 5q31 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Malaria, intensity of infection} (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Schistosoma mansoni infection, susceptibility/resistance to} (2) | 5q31-q33 | CTNNA1 | catenin (cadherin-associated protein), alpha 1, 102kDa | 0.713 |
| {Autism, susceptibility to, 6} (2) | 17q11 | NF1 | neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) | 0.713 |
| Pseudohyperkalemia, familial, 2, due to red cell leak (2) | 2q35-q36 | OBSL1 | obscurin-like 1 | 0.713 |
| Syndactyly, type 1 (2) | 2q34-q36 | OBSL1 | obscurin-like 1 | 0.713 |
| {Systemic lupus erythematosus with nephritis, susceptibility to, 2} (2) | 2q34-q35 | OBSL1 | obscurin-like 1 | 0.713 |
| {Tuberculosis, susceptibility to} (2) | 2q35 | OBSL1 | obscurin-like 1 | 0.713 |
| Atrial septal defect, secundum type (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Deafness, autosomal recessive 66 (2) | 6p22.3-p21.2 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Epilepsy, juvenile myoclonic 3 (2) | 6p21 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Immunoglobulin A deficiency (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Laryngeal adductor paralysis (2) (?) | 6p21.3-p21.2 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Myasthenia gravis with thymus hyperplasia (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Otosclerosis 3 (2) | 6p22.3-p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Panbronchiolitis, diffuse (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Spinocerebellar ataxia, autosomal recessive 3 (2) | 6p23-p21 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Wegener granulomatosis (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| {Azoospremia, nonobstructive} (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| {Cataract, age-related cortical, susceptibility to} (2) | 6p12-q12 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| {Diabetes mellitus, insulin-dependent-1} (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| {Macroglobulinemia, Waldenstrom, susceptibility to, 1} (2) | 6p21.3 | HLA-DQA2 | major histocompatibility complex, class II, DQ alpha 2 | 0.706 |
| Ataxia, sensory, autosomal dominant (2) | 8p12-q12.1 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| Dystonia-6, torsion (2) | 8p21-q22 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| Preauricular fistulae, congenital (2) (?) | 8q11.1-q13.3 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| Spastic paraplegia-5A (2) | 8p12-q13 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| {Alzheimer disease 12} (2) | 8p12-q22 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| {Mycobacterium tuberculosis, susceptibility to, 2} (2) | 8q12-q13 | RAB2A | RAB2A, member RAS oncogene family | 0.704 |
| Aortic aneurysm, familial thoracic 2 (2) | 5q13-q14 | SERINC5 | serine incorporator 5 | 0.703 |
| Capillary malformations, hereditary (2) | 5q13-q22 | SERINC5 | serine incorporator 5 | 0.703 |
| Fibromatosis, gingival, 2, 135300 (2) | 5q13-q22 | SERINC5 | serine incorporator 5 | 0.703 |
| Myoclonic epilepsy, juvenile, 4 (2) | 5q12-q14 | SERINC5 | serine incorporator 5 | 0.703 |
| Striatal degeneration, autosomal dominant (2) | 5q13.3-q14.1 | SERINC5 | serine incorporator 5 | 0.703 |
| Epilepsy, myoclonic, benign adult familial, type 2 (2) | 2p11.1-q12.2 | TGOLN2 | trans-golgi network protein 2 | 0.702 |
| Retinitis pigmentosa-28 (2) | 2p15-p11 | TGOLN2 | trans-golgi network protein 2 | 0.702 |
| Aneurysm, intracranial berry, 5 (2) | 2p15-q14 | SPTBN1 | spectrin, beta, non-erythrocytic 1 | 0.701 |
| Epilepsy, myoclonic, benign adult familial, type 2 (2) | 2p11.1-q12.2 | SPTBN1 | spectrin, beta, non-erythrocytic 1 | 0.701 |
| Spinocerebellar ataxia 25 (3) | 2p21-p13 | SPTBN1 | spectrin, beta, non-erythrocytic 1 | 0.701 |
| Cayler cardiofacial syndrome (2) | 22q11 | IGL@ | immunoglobulin lambda locus | 0.696 |
